氯吡格雷抵抗与卒中防治  

Clopidogrel resistance and the prevention and treatment of stroke

作　　者：黄立安[1] 张世军[1] 徐安定[1] 宋雪文[1] 

机构地区：[1]暨南大学第一附属医院神经内科,广州510632

出　　处：《国际脑血管病杂志》2012年第3期219-222,共4页International Journal of Cerebrovascular Diseases

基　　金：基金项目：广东省科技计划项目（20118050300012）

摘　　要：氯吡格雷是缺血性卒中治疗的基本药物，被多国卒中治疗指南所推荐，广泛应用于临床。有不少缺血性卒中患者在经过规范氯吡格雷治疗后仍然复发卒中，因此必须重视氯吡格雷抵抗现象。文章对氯吡格雷抵抗的生化机制、基因多态性、实验室检测及其应对措施进行了综述。Clopidogrel is an essential drug for the treatrtment of ischemic stroke. It has been recormmended by the multinational stroke treatment guidelines and has been widely used in clinical practice. Many patients with ischemic stroke may still have stroke recurrence after the standard treatrtment of clopidogrel; therefore, we must pay attention to the phenomenon of clopidoffel resistance. This article reviews the biochemical mechanisms, gene polymorphism, laboratory testing and response measures of clopidogrel resistance.

关 键 词：氯吡格雷 抗药性 血小板聚集抑制药 卒中 脑缺血 

分 类 号：R743.3[医药卫生—神经病学与精神病学]